Clinical Trials Browser

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

NCT02152982 2026-04-13

Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 2/3 Active not recruiting

447 enrolled 20 charts

CNSSarcoma

Glioblastoma, Gliosarcoma

NCT03911388 2026-04-13

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

Phase 1 Recruiting

24 enrolled

CNSSarcoma

Choroid Plexus Carcinoma, Astrocytoma, Brain Diseases, Brain Neoplasms, Central Nervous System Diseases, Cerebellar Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Neoplasm Metastasis, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Glandular and Epithelial, Neoplasms, Nerve Tissue, Nervous System Diseases, Nervous System Neoplasms, Oligodendroglioma, Virus Diseases, Central Nervous System Neoplasms, Neuroectodermal Tumors, Neuroectodermal Tumors, Primitive, Neoplasms, Neuroepithelial, Gliosarcoma, Rhabdoid Tumor

NCT04528680 2026-04-13

SC9/ABX

Phase 1/2 Active not recruiting

57 enrolled

CNSSarcoma

Glioblastoma, Gliosarcoma

NCT07422363 2026-04-13

Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma

Phase 1 Not yet recruiting

30 enrolled

CNSSarcoma

Glioblastoma, Gliosarcoma

NCT07134842 2026-04-09

WinGlio-ipi

Phase 1 Recruiting

16 enrolled

CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT07301268 2026-04-08

GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma

Phase 2 Recruiting

36 enrolled

CNSSarcoma

Astrocytoma, Glioblastoma, Gliosarcoma

NCT03115333 2026-04-03

DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma

Phase NA Active not recruiting

146 enrolled

CNSSarcoma

Glioblastoma, Gliosarcoma

NCT05095376 2026-04-03

Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

Phase 3 Active not recruiting

265 enrolled

CNSSarcoma

Glioblastoma, Gliosarcoma

NCT02455557 2026-03-30

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Phase 2 Active not recruiting

66 enrolled 11 charts

CNSSarcoma

Glioblastoma, Gliosarcoma

NCT06934889 2026-03-30

Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma

Phase 1 Recruiting

60 enrolled

CNSSarcoma

Glioblastoma, Gliosarcoma

NCT03197506 2026-03-25

Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma

Phase 2 Active not recruiting

52 enrolled 19 charts

CNSSarcoma

Glioblastoma, Gliosarcoma

NCT03478462 2026-03-18

CLOVER-2

Phase 1 Active not recruiting

30 enrolled

CNSGenitourinaryLymphoidSarcoma

Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioblastoma, Glioma, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Primitive, Neoplasms, Neuroepithelial, Gliosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT04817254 2026-03-18

Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Phase 2 Active not recruiting

47 enrolled

CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

NCT03896568 2026-03-05

MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

Phase 1 Recruiting

36 enrolled

CNSSarcoma

Astrocytoma, Glioblastoma, Glioma, Gliosarcoma

NCT04396860 2026-03-05

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

Phase 2/3 Completed

159 enrolled 17 charts

Sarcoma

Gliosarcoma

NCT02942264 2026-02-23

Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma

Phase 1/2 Terminated

53 enrolled 22 charts

CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Recurrence, Gliosarcoma

NCT05756985 2026-02-04

Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue

Recruiting

120 enrolled

CNSSarcoma

Glioblastoma, Gliosarcoma

NCT04216329 2026-01-23

Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

Phase 1 Active not recruiting

11 enrolled 19 charts

CNSSarcoma

Glioblastoma, Gliosarcoma

NCT04991870 2026-01-23

Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM

Phase 1 Recruiting

25 enrolled

Sarcoma

Gliosarcoma

NCT05084430 2026-01-22

Study of Pembrolizumab and M032 (NSC 733972)

Phase 1/2 Recruiting

28 enrolled

CNSSarcoma

Astrocytoma, Glioblastoma, Recurrence, Gliosarcoma

Clinical Trials

Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas

Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

SC9/ABX

Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma

WinGlio-ipi

GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma

DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma

Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma

Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma

CLOVER-2

Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma

Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue

Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM

Study of Pembrolizumab and M032 (NSC 733972)